Dry Eye Disease: Causes, Symptoms, and Evidence-Based Management
Dry eye disease (DED) is a multifactorial disorder of the tear film and ocular surface causing discomfort, visual disturbance, and tear film instability. Prevalence: 5–30% (increases with age, female sex). It is a chronic, often progressive condition requiring long-term management.
Pathophysiology (TFOS DEWS II Classification)
- Aqueous-Deficient DED: Lacrimal gland dysfunction (Sjögren's, age, medications, graft-vs-host disease).
- Evaporative DED: Meibomian gland dysfunction (MGD) — 86% of DED. Lipid layer deficiency → rapid tear evaporation.
- Mixed: Most patients have both components.
- Neuropathic: Corneal nerve dysfunction (post-LASIK, herpetic, diabetes).
Risk Factors
- Aging, menopause (androgen decline → MGD).
- Screen use (↓ blink rate, incomplete blinks).
- Contact lens wear.
- Medications: Antihistamines, antidepressants, diuretics, isotretinoin, beta-blockers.
- Autoimmune: Sjögren's, RA, SLE, scleroderma.
- Environment: Low humidity, wind, AC/heat, pollution.
- Rosacea (ocular).
Symptoms
- Foreign body sensation, grittiness, burning, stinging.
- Paradoxical tearing (reflex).
- Blurred vision (improves with blink).
- Light sensitivity, eye fatigue, contact lens intolerance.
- Worse late day, reading, screen use, dry environments.
Diagnostic Evaluation
- Symptom questionnaires: OSDI, SPEED, DEQ-5.
- TBUT (tear breakup time) <10 sec.
- Schirmer I <5 mm/5 min (aqueous deficiency).
- Ocular surface staining (fluorescein cornea, lissamine green conjunctiva).
- Meibography (MGD structure).
- Tear osmolarity >308 mOsm/L or inter-eye difference >8.
- MMP-9 (InflammaDry) — inflammatory marker.
Stepwise Management
Level 1: Education + Environmental + Lubrication
- Preservative-free artificial tears (carboxymethylcellulose, hyaluronic acid, HP-guar) — 4–6×/day.
- Gel/ointment at bedtime.
- Humidifier (30–50%), avoid direct airflow, 20-20-20 rule (screens).
- Omega-3 (1–2 g EPA+DHA).
- Lid hygiene (warm compresses 10 min + lid scrubs).
Level 2: Anti-Inflammatory + Therapeutic
- Topical cyclosporine 0.05% (Restasis) or 0.09% (Cequa) — BID; 3–6 mo for full effect.
- Lifitegrast 5% (Xiidra) — BID; faster onset.
- Short-course topical steroid (loteprednol, fluorometholone) — pulse then taper.
- Punctal plugs (collagen → silicone) — if aqueous deficient, no active inflammation.
- Oral doxycycline/azithromycin (anti-inflammatory, MGD) — low dose, 1–3 mo.
Level 3: Advanced
- Autologous serum tears (20–50%).
- Thermal pulsation (LipiFlow), IPL (intense pulsed light) for MGD.
- Amniotic membrane graft (Prokera).
- Scleral lenses (protect surface, vault cornea).
- Severe: Systemic immunosuppression (Sjögren's), tarsorrhaphy, salivary gland transplant.
Newer Therapies
- Varenicline nasal spray (Tyrvaya) — cholinergic agonist → tear production.
- Perfluorohexyloctane (Miebo) — evaporative DED/MGD (lipid layer replacement).
- Reproxalap (RASP modulator) — investigational.
DED is chronic; management is iterative. Partner with an eye care provider for personalized step therapy.
Eye & Vision Disorders - Related Articles
- Stye Treatment: Medications & Relief | EyeCare Experts
- Polymer Contact Lenses: History, Key Properties, and Their Impact on Eye Health
- Is It Time for Reading Glasses? Common Signs & Symptoms
- Blind Rivets: Definition, Applications, and Installation Steps
- A Brief History of Contact Lenses: From Da Vinci to Modern Innovation
- Revive Your Contacts: How to Rehydrate Dried-Out Contact Lenses
- Concussion-Associated Eye Twitching (Nystagmus): Mechanism and Prognosis
